Ayahuasca vs psilocybin: how they differ and what to ask
Ayahuasca and psilocybin mushrooms are the two substances people most often weigh up when they first look at ceremonies. Both are classic psychedelics, both act mainly on the brain’s serotonin system, and both can bring up intense emotions and memories. In practice they differ a lot: in how long they last, what they do to your body, which medicines they clash with, the traditions behind them, and how much research exists.
This guide compares them so you can ask better questions. It won’t tell you which one to take, and it doesn’t cover amounts or how to obtain either. If you take any regular medication or have a health condition, start with our guide on medications and health conditions.
The short version
- Ayahuasca is a brew of two plants. Psilocybin is a compound found in certain mushrooms.
- In clinical studies, the main effects of ayahuasca faded within about four hours and those of psilocybin within about six. Ceremonies often run longer than the effects of one serving.
- Vomiting is common with ayahuasca and much less common with psilocybin.
- Ayahuasca contains a compound that blocks a key enzyme, which makes its medication interactions more dangerous.
- Psilocybin has far more clinical research behind it. Ayahuasca has one small placebo-controlled trial.
- Both carry psychological risks, and both are a poor idea for people with a personal or family history of psychosis or mania.
What each one is
Ayahuasca is usually made by brewing a vine, Banisteriopsis caapi, with the leaves of a shrub, Psychotria viridis. The leaves contain DMT, a short-acting psychedelic. Swallowed on its own, DMT is broken down in the gut and liver by an enzyme called monoamine oxidase before it can take effect. The vine contains harmine and related compounds that block that enzyme for a while, which lets the DMT work. That same enzyme block is the source of its most serious drug interactions.
Psilocybin occurs naturally in some species of mushroom and, like DMT, acts on serotonin receptors in the brain. In ceremonies, people usually eat dried mushrooms or drink them as a tea. Clinical trials use psilocybin made in a lab, which comes at a precise, known strength. Mushrooms don’t.
How long the effects last
In research settings, ayahuasca’s effects began roughly 40 minutes after drinking, peaked between one and two hours, and had mostly faded by about four hours. In a clinical study of psilocybin, effects became noticeable 30 to 60 minutes after taking it, peaked at two to three hours, and had dropped to negligible levels by around six hours.
A ceremony is a different thing from a single dose. Ayahuasca ceremonies are often held at night, and some centers offer a second serving. Psilocybin ceremonies vary more. Ask how long yours lasts, whether more will be offered, and what happens if you say no.
What they do to your body
Vomiting is the most obvious physical difference. In the only placebo-controlled ayahuasca trial, 57% of people who drank ayahuasca vomited and 71% felt nauseous. In the Global Ayahuasca Survey of over 8,000 people, 62% reported vomiting or nausea. Many traditions see this purging as part of the healing, and researchers explain it by the brew’s effect on serotonin in the gut and on the nerve that controls vomiting. Diarrhea can happen too. In studies, ayahuasca raised blood pressure and heart rate modestly.
With psilocybin, nausea happens but is usually milder. In a small clinical study of people with depression, four of 12 had mild, short-lived nausea, and four had a headache. In a larger trial of 233 people, the most common adverse events were headache, nausea and dizziness.
Medication risks
This is where the difference matters most for safety. Because ayahuasca blocks monoamine oxidase, combining it with medicines that raise serotonin, including SSRI antidepressants, can cause serotonin syndrome, a reaction that can be dangerous. A 2019 review also flags tricyclic antidepressants, some opioids and some migraine medicines, and notes that the compounds in the vine affect liver enzymes that process many other drugs.
Psilocybin interacts with medicines too, and clinical trials routinely exclude people on certain drugs. With either substance, tell the center about every medicine and supplement you take, and never stop or change a prescription without the person who prescribed it. A careful center will ask, and will sometimes turn you away or ask you to wait. That’s a good sign.
Psychological risks
Both can be frightening. In a survey of nearly 2,000 people about their hardest experience with psilocybin mushrooms, 39% ranked it among the five most challenging experiences of their lives, 11% said they had put themselves or others at risk of physical harm, and 7.6% of those whose experience was more than a year earlier had sought treatment for lasting psychological symptoms. Risky behavior was more likely when the experience was longer or harder and when physical comfort and social support were missing. Most respondents still said they had benefited.
For ayahuasca, the Global Ayahuasca Survey found that 55% of respondents reported some psychological adverse effect, most often seeing or hearing things others didn’t or feeling disconnected. Most of them saw it as part of a positive process, and about 12% of them said they needed professional support.
For both, the people at highest risk of a serious reaction are those with a personal or family history of psychosis or mania. Safety guidelines for psychedelic research exclude them, and so should a careful center.
Traditions and settings
Ayahuasca comes from the Amazon, where many Indigenous peoples use it in healing and spiritual practice, and from Brazilian churches founded in the 20th century that use it as a sacrament. Ceremonies are typically held in the dark, in a group, led by a healer or facilitator who sings or plays music. Many centers ask you to follow a special diet beforehand.
Psilocybin mushrooms were used in religious and healing rites in Mesoamerica, and the Mazatec ceremonies of Oaxaca brought them to the outside world in the 1950s. Today you’ll find them in ceremonies modeled on those traditions, in modern retreat formats, and in regulated settings. In Oregon, for example, adults 21 and over can take psilocybin at a licensed service center under the supervision of a licensed facilitator, without a medical referral, after a required preparation session.
How much research exists
Psilocybin has been tested in many clinical trials, including randomized trials for depression and alcohol use disorder, some with hundreds of participants. Ayahuasca has been studied mostly through surveys and before-and-after studies of retreat participants, with one small placebo-controlled trial for depression. Even the psilocybin research has real limits, and neither body of research tells you what a ceremony will do for you. Our guides to the key studies and to ayahuasca research go through the details.
Legal status, briefly
This isn’t legal advice, and laws change and differ between countries and states. In the US, as of October 2026, psilocybin and DMT are both controlled under federal law. Oregon and Colorado run state programs for supervised psilocybin use. A small number of religious groups have won the right to use ayahuasca in ceremonies, most notably through a 2006 Supreme Court case brought by a Brazilian church, and that ruling applies to those groups. Our legal guides cover the details.
Questions to ask yourself
- Do I take any medicine or supplement that could interact? Have I talked to my prescriber?
- How do I feel about vomiting, possibly several times, in a room with other people?
- Do I want a practice tied to a particular tradition, or a more secular setting?
- Am I willing to travel, and what would I do if something went wrong far from home?
- Does the center screen me properly for this specific substance?
One last point: some retreats offer both, sometimes days apart. Each substance carries its own risks, and screening for one doesn’t cover the other. If a center offers both, ask how it screens for each and how much time it leaves between them.
More guides
- What ayahuasca is
- What psilocybin is
- Medications and health conditions: who shouldn’t sit
- What to expect at a psilocybin ceremony
- What happens in an ayahuasca ceremony
- Psilocybin in Oregon and Colorado: the legal programs
Whichever you’re considering, past participants’ reviews are a good way to learn how a center screens, staffs its ceremonies and follows up. You can search the Safe Ceremonies listings and compare ayahuasca and psilocybin and mushroom centers.
Sources
- Hamill J, Hallak J, Dursun SM, Baker G (2019). Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness. Current Neuropharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC6343205/
- Carhart-Harris RL, Bolstridge M, Rucker J, et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(16)30065-7
- Palhano-Fontes F, Barreto D, Onias H, et al. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC6378413/
- Bouso JC, Andión Ó, Sarris JJ, et al. (2022). Adverse effects of ayahuasca: results from the Global Ayahuasca Survey. PLOS Global Public Health. https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0000438
- Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206443
- Carbonaro TM, Bradstreet MP, Barrett FS, et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms. Journal of Psychopharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC5551678/
- Johnson MW, Richards WA, Griffiths RR (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC3056407/
- dos Santos RG, Bouso JC, Hallak JEC (2017). Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Therapeutic Advances in Psychopharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC5433617/
- Skalski P, Pękacka-Falkowska K, Pluto-Prądzyńska A, Owecki MK (2026). Psilocybin in neuropsychiatric disorders: seeking valuable evidence in history, pure science, clinical trials and real-world data. Brain Sciences. https://pmc.ncbi.nlm.nih.gov/articles/PMC13115139/
- Oregon Health Authority. What are psilocybin services? (checked October 2026). https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-What-are-Psilocybin-Services.aspx
- Colorado Division of Professions and Occupations. Natural medicine (checked October 2026). https://dpo.colorado.gov/NaturalMedicine
- Gonzales v. O Centro EspÃrita Beneficente União do Vegetal, 546 U.S. 418 (2006). Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/supct/html/04-1084.ZS.html
Photo: Sunlight on a Woodland Path in Autumn by @dartmoorgiant, CC BY 3.0.
